Pharmacoeconomic evaluation of recombinant human acidic fibroblast growth factor in the treatment of diabetic foot ulcers
HUANG Guo
SUI Meng-yun
ZHU He
HAN Sheng
SHI Lu-wen
Abstract：Objective:To conduct a pharmacoeconomic evaluation on recombinant human acidic fibroblast growth factor(rh-aFGF)compared to conventional therapy in the treatment of diabetic foot ulcers(DFU),providing an evidence-based support for rational clinical medication and healthcare decision-making.Methods:A Meta-analysis was conducted to compare the efficacy and safety of the two treatment methods.A decision tree model was constructed to perform cost-effectiveness and sensitivity analyses of the two treatment approaches for DFU.Results:A total of 11 studies,involving in 17 randomized controlled trials(RCTs),were included in this analysis,covering 1 118 patients with DFU.The Meta-analysis indicated that the effective rate of the rh-aFGF group was significantly higher than that of the saline group[RR=1.23,95%CI(1.06,1.44),P=0.008].The complete wound healing time was significantly shorter in the rh-aFGF group than that in the saline group[MD=-9.97,95%CI(-13.87,-6.08),P<0.01],with both groups demonstrating good safety.The cost-effectiveness analysis showed that the rh-aFGF regimen was less costly and had a higher overall effectiveness rate than the saline regimen,indicating economic advantages for rh-aFGF.Sensitivity analysis revealed that the results of the base analysis were relatively robust.Conclusion:The rh-aFGF regimen is superior to the conventional treatment(saline)in terms of both clinical efficacy and cost-effectiveness for treating DFU patients,making it the preferred treatment option.
Keywords：recombinant human acidic fibroblast growth factordiabetic foot ulcersMeta-analysisdecision treecost-effectiveness analysis
Publication Date：2025-06-30
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：9( 1313-1321 )